Humoral and cellular immunities elicited by HIV-1 vaccination

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• Plasmid DNA immunization can induce immune responses against viral antigens.
• HIV-1 envelope glycoprotein 120 (gp120) and rev proteins are key targets for vaccine development.

Purpose of the Study:

• To evaluate the efficacy of plasmid DNA vaccines expressing HIV-1 gp120 or rev proteins in eliciting immune responses.
• To assess both humoral and cellular immunity induced by these DNA vaccines in preclinical models.

Main Methods:

• Mice and nonhuman primates were intramuscularly injected with plasmids encoding tPA-gp120 or rev.
• Humoral responses were measured by ELISA for antibody production.
• Cellular responses were assessed via splenocyte proliferation, cytotoxic T lymphocyte (CTL) activity, and cytokine profiling (gamma-interferon, IL-4).

Main Results:

• DNA vaccination elicited antigen-specific antibody responses against HIV-1 gp120 and V2 peptide neutralization epitope.
• Vaccinated animals showed gp120-specific T cell proliferation and MHC Class I-restricted CTL activity.
• Primarily T helper 1 (Th1)-like responses were induced, characterized by high gamma-interferon production.
• Immune responses were dose-dependent, boostable, and persisted for over six months.
• Nonhuman primates developed neutralizing antibodies against HIV.

Conclusions:

• Plasmid DNA vaccines effectively induce significant humoral and cellular immune responses against HIV-1 antigens.
• The induced immune responses are characterized by a Th1-like profile and are long-lived.
• DNA vaccination represents a promising strategy for developing an effective HIV vaccine.